These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 6695591

  • 1. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
    Melamed E, Hefti F.
    Adv Neurol; 1984; 40():149-57. PubMed ID: 6695591
    [No Abstract] [Full Text] [Related]

  • 2. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.
    Melamed E, Hefti F, Wurtman RJ.
    Ann Neurol; 1980 Dec; 8(6):558-63. PubMed ID: 6260009
    [Abstract] [Full Text] [Related]

  • 3. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E.
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract] [Full Text] [Related]

  • 4. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [Abstract] [Full Text] [Related]

  • 5. Variations in the "on-off" phenomenon.
    Duvoisin RC.
    Adv Neurol; 1974 Apr; 5():339-40. PubMed ID: 4440582
    [No Abstract] [Full Text] [Related]

  • 6. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E.
    Adv Neurol; 1990 Apr; 53():61-6. PubMed ID: 2173376
    [No Abstract] [Full Text] [Related]

  • 7. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O.
    Neurodegener Dis; 2008 Apr; 5(3-4):114-7. PubMed ID: 18322366
    [Abstract] [Full Text] [Related]

  • 8. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
    Darmopil S, Muñetón-Gómez VC, de Ceballos ML, Bernson M, Moratalla R.
    Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
    [Abstract] [Full Text] [Related]

  • 9. Partial damage to nigrostriatal bundle: compensatory changes and the action of L-dopa.
    Zigmond MJ, Abercrombie ED, Stricker EM.
    J Neural Transm Suppl; 1990 Feb; 29():217-32. PubMed ID: 2193107
    [Abstract] [Full Text] [Related]

  • 10. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
    Nakao N, Shintani-Mizushima A, Kakishita K, Itakura T.
    Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
    [Abstract] [Full Text] [Related]

  • 11. Intermittent levodopa therapy in parkinsonism.
    Koller WC.
    Adv Neurol; 1983 Sep; 37():45-50. PubMed ID: 6407286
    [Abstract] [Full Text] [Related]

  • 12. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O.
    Adv Neurol; 1993 Sep; 60():140-7. PubMed ID: 8420131
    [No Abstract] [Full Text] [Related]

  • 13. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA, Weiner N.
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [Abstract] [Full Text] [Related]

  • 14. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A.
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [Abstract] [Full Text] [Related]

  • 15. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
    Schneider JS, Kean A, DiStefano L.
    J Neurosci Res; 1995 Sep 01; 42(1):117-23. PubMed ID: 8531220
    [Abstract] [Full Text] [Related]

  • 16. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H, Aimi Y, Nagatsu I, Taki K, Kudo M, Arai R.
    Neurosci Res; 2007 Sep 01; 59(1):1-7. PubMed ID: 17586078
    [Abstract] [Full Text] [Related]

  • 17. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW.
    Mov Disord; 2008 Sep 01; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [Abstract] [Full Text] [Related]

  • 18. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA, Girotti F, Giovannini P, Parati E.
    J Neural Transm Suppl; 1986 Sep 01; 22():189-99. PubMed ID: 3537210
    [Abstract] [Full Text] [Related]

  • 19. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease.
    Anglade P, Tsuji S, Javoy-Agid F, Agid Y, Hirsch EC.
    Ann Neurol; 1995 Feb 01; 37(2):265-72. PubMed ID: 7847868
    [Abstract] [Full Text] [Related]

  • 20. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A.
    J Neural Transm Suppl; 1983 Feb 01; 19():153-61. PubMed ID: 6321646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.